Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

About

Brief Summary

The goal of this clinical trial is to compare ARINA-1 plus Standard of Care vs Standard of Care alone. The main question it aims to answer are:

Evaluate the effectiveness of ARINA-1 in preventing bronchiolitis obliterans syndrome (BOS) progression in participants with a bilateral lung transplant
To evaluate the effectiveness of ARINA-1 on improving quality of life decline and preventing or delaying the use of augmented immunosuppression in participants with pre-BOS relative to SOC.

Participants will have clinic visits at screening, randomization (day 1) and weeks 4, 12, 18, and 24. After week 24, participants will have clinic visits at weeks 32, 40, and 48.

Participants will also have a telehealth visit on day 2 and phone calls to assess adverse events (AEs), serious adverse events (SAEs), and review patient education will occur during weeks 5, 8, 36, and 44.

Primary Purpose

Treatment

Study Type

Interventional

Phase

Phase 3

Eligibility

Gender

All

Healthy Volunteers

No

Minimum Age

18 Years

Maximum Age

75 Years

Inclusion Criteria:

Bilateral lung transplant >12 months from the time of Visit 1 / Randomization
Age 18-75 years old at the time of consent
Routinely followed at enrolling site
Willing and able to comply with visit schedule and at-home requirements
10-24% decrease in FEV1 from the post-transplant baseline within the last 12 months.
Capable of giving informed consent
On a stable maintenance regimen of azithromycin for >4 weeks prior to the Screening Visit
On a stable 3-agent immunosuppression regimen that includes a steroid, a calcineurin inhibitor (CNI), and cell cycle inhibitor (e.g., mycophenolate, azathioprine) >4 weeks prior to Screening
If a woman of childbearing potential (WOCBP), must agree to use a reliable method of birth control for the entire duration of the study.

Exclusion Criteria:

Positive urine pregnancy test at screening and baseline visit
Diagnosis of active congestive heart failure or symptomatic coronary artery disease > grade 3 based on the New York Heart Association Functional Classification (NYHA) criteria
Restrictive allograft syndrome (RAS) defined by radiographic interstitial or alveolar opacities on chest X-ray or CT scan that are consistent with RAS
Have advanced BOS, defined by >24% decrease in FEV1 in post-transplant baseline
A diagnosis of probable antibody-mediated rejection (AMR) <12 months prior to the baseline visit
Donor-specific antibodies (DSA) identified <6 months prior to the baseline visit. *The presence of DSA >6 months from the baseline visit is acceptable for enrollment into the study.
Unresolved diffuse alveolar damage
Receiving mechanical ventilation
Chronic kidney disease stage IV or higher, including on dialysis
Initiating a new maintenance therapy or changing immunosuppression maintenance therapy (e.g., changing tacrolimus to cyclosporine) <14 days prior to the baseline visit.
Currently using an mTOR inhibitor or azathioprine
Initiating or changing antibiotic (including azithromycin), antiviral, or antifungal therapy <14 days prior to the baseline visit.
Use of alemtuzumab <6 months prior to the baseline visit
Use of anti-thymocyte therapies (e.g., anti-thymocyte globulin) or photopheresis <90 days prior to the Screening Visit. Prior use of Trikafta (elexacaftor, ivacaftor, and tezacaftor is allowed as long as the participant has been on stable dose for >90 days prior to the Screening Visit.
Initiating a multivitamin or other supplement (inhaled, oral, or IV) containing vitamin C, glutathione, or N-acetylcysteine <90 days prior to the baseline visit
Significant unstable comorbidities, in the opinion of the site investigator
Allery or previous adverse reaction to azithromycin
A diagnosis of dynamic collapse / tracheobrochomalacia <90 days of the baseline visit.
Subjects currently participating in, or who have participated in an interventional (drug or device) clinical study <30 days of the baseline visit.
Have been diagnosed with ARAD within 6 weeks of the Screening Visit.
Have used belatacept <6 months prior to Clinic Visit 1
Have had bronchial stents or cryotherapy within 12 months of the Screening Visit